Predictors of mortality among HIV infected patients taking antiretroviral treatment in Ethiopia: a retrospective cohort study by Sibhatu Biadgilign et al.
Biadgilign et al. AIDS Research and Therapy 2012, 9:15
http://www.aidsrestherapy.com/content/9/1/15RESEARCH Open AccessPredictors of mortality among HIV infected
patients taking antiretroviral treatment in
Ethiopia: a retrospective cohort study
Sibhatu Biadgilign1, Ayalu A Reda2* and Tesfaye Digaffe3Abstract
Background: Studies indicate that there is high early mortality among patients starting antiretroviral treatment in
sub-Saharan Africa. However, there is paucity of evidence on long term survival of patients on anti-retroviral
treatment in the region. The objective of this study is to examine mortality and its predictors among a cohort of
HIV infected patients on anti-retroviral treatment retrospectively followed for five years.
Methods: A retrospective cohort study was conducted among HIV infected patients on ART in eastern Ethiopia. Cox
regression and Kaplan-Meier analyses were performed to investigate factors that influence time to death and
survival over time.
Result: A total of 1540 study participants were included in the study. From the registered patients in the cohort,
the outcome of patients as active, deceased, lost to follow up and transfer out was 1005 (67.2%), 86 (5.9%), 210
(14.0%) and 192 (12.8%) respectively. The overall mortality rate provides an incidence density of 2.03 deaths per 100
person years (95% CI 1.64 - 2.50). Out of a total of 86 deaths over 60 month period; 63 (73.3%) died during the first
12 months, 10 (11.6%) during the second year, and 10 (11.6%) in the third year of follow up. In multivariate analysis,
the independent predictors for mortality were loss of more 10% weight loss, bedridden functional status at baseline,
≤ 200 CD4 cell count/ml, and advanced WHO stage patients.
Conclusion: A lower level of mortality was detected among the cohort of patients on antiretroviral treatment in
eastern Ethiopia. Previous history of weight loss, bedridden functional status at baseline, low CD4 cell count and
advanced WHO status patients had a higher risk of death. Early initiation of ART, provision of nutritional support and
strengthening of the food by prescription initiative, and counseling of patients for early presentation to treatment is
recommended.Introduction
Development of highly active antiretroviral treatment
(ART) in the mid-1990s revolutionized the care of
HIV-infected patients and led to marked reductions in
HIV-associated morbidity and mortality in many indus-
trialized countries [1,2]. ART has clearly shown to be
effective in reducing mortality among those who remain
in treatment and adhere to therapy [2-4]. In recent years
in developing countries with a high burden of AIDS, ART
has become more widely available. According to estima-
tion by the World Health Organization (WHO), about 6* Correspondence: ayaluaklilu@yahoo.com; a.reda@haramaya.edu.et
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reproduction in any medium, provided the or650 000 patients were receiving ART in low- and middle-
income countries by the end of 2010 [5], this is a huge
improvement from the levels in 2003 [6,7]. Two sub-Sa-
haran African countries, Botswana and Rwanda, have
achieved universal access target (treatment coverage of
80% or more of patients in need) at the end of 2009 [7],
while countries such as Ethiopia, Zambia, Namibia and
Senegal are moving closer to the same target having cov-
ered 50-80% of patients in need of treatment [7]. Due
to this morbidity and mortality among HIV-infected
persons have dramatically decreased [8,9].
The primary goals of antiretroviral therapy are pre-
venting HIV-related morbidity and mortality, and im-
proving quality of life by restoring immunologic function
through suppression of viral load [10]. Many studiesral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.













Male 574 (37.3) 431 (37.6) 131 (36.3)
Female 963 (62.5) 715 (62.4) 230 (63.7)
Age (Median, IQR) 32 (28–40) 32 (28.0–40.0) 35 (28.0–40.0)
Religion
Muslim 305 (19.8) 220 (19.1) 76 (21.1)
Orthodox 1074 (69.9) 812 (70.7) 241 (66.8)
Protestant 144 (9.4) 103 (9.0) 41 (11.4)
Others 14 (0.9) 14 (1.2) 3 (0.8)
Education
No education 261 (17.0) 185 (16.1) 67 (18.6)
Primary 681 (44.3) 490 (42.7) 178 (49.3)
Secondary 500 (32.5) 391 (34.1) 102 (28.3)
Tertiary 96 (6.2) 81 (7.1) 14 (3.9)
Marital status
Never Married 287 (18.6) 217 (18.9) 65 (18.0)
Married 606 (39.4) 475 (41.4) 124 (34.3)
Separated 288 (18.7) 206 (17.9) 74 (20.5)
Divorced 116 (7.5) 89 (7.8) 22 (6.1)
Widowed 242 (15.7) 161 (14.0) 76 (21.1)
Occupation
Merchant 75 (7.4) 60 (7.7) 15 (6.7)
Gov. Employee 157 (15.5) 122 (15.6) 33 (14.8)
Non-Gov. Employee 41 (4.1) 34 (4.4) 7 (3.1)
Day Laborer 174 (17.2) 130 (16.7) 44 (19.7)
Job-less 402 (39.7) 303 (38.8) 94 (42.2)
Other 163 (16.2) 131 (16.8) 30 (13.5)
Past co-trimoxazole treatment
Yes 758 (49.2) 576 (50.1) 171 (47.4)
No 782 (50.8) 573 (49.9) 190 (52.6)
WHO stage at baseline
Stage I 92 (6.0) 76 (6.7) 15 (4.2)
Stage II 348 (22.7) 282 (24.7) 63 (17.5)
Stage III 890 (58.2) 633 (55.5) 239 (66.6)
Stage IV 200 (13.1) 150 (13.1) 42 (11.7)
Baseline CD4 count,
median (IQR)
135 (76.0–198.3) 107 (64.0–154.0) 253 (223.3–304.0)
Weight at baseline
in kgs, median (IQR)
50.0 (44.0–56.0) 50 (44.0–56.0) 50 (45.0–57.0)
¥Number and percentages unless indicated otherwise. IQR, inter-quartile rage.
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ing antiretroviral treatment in sub-Saharan Africa [4].
One of the reasons cited for this is that despite better
availability of ART, people are still diagnosed late and
thus start ART at later stages of the HIV disease [11].
In Ethiopia, there were more than 222,000 patients on
antiretroviral treatment at the end of 2010 [6]. ART has
improved survival of patients with HIV/AIDS and
improved the quality of life of patients in the country
[12]. In Ethiopia, there are no studies reporting the long
term survival of patients on antiretroviral treatment.
Such studies could provide valuable information to
evaluate the ART program in the country. The objective
of this study is to examine mortality and its predictors
among a cohort of HIV infected patients on antiretro-
viral treatment retrospectively followed for five years.
Methods
Study area and period
The study was conducted in Hiwot Fana, Jugal and Dil
Chora hospitals located in eastern Ethiopia. Data was
collected from September to November 2010.
Study design
A retrospective cohort study was conducted among HIV
patients on ART. A random sample of 1537 patients that
started treatment between September 11, 2005 and Sep-
tember 10, 2008 were included in the study and retro-
spectively followed up for an additional two years until
September 10, 2010. The patients’ identification numbers
were used to generate the necessary sample from the
records of the hospitals for extracting data.
Socio-demographic characteristics, baseline and follow
up clinical and laboratory measurement information, and
treatment outcomes were abstracted from patients' cards.
The primary outcome measure was patient survival,
while secondary outcome measures included CD4 count
and body weight.
Data collection and quality control
A standard questionnaire was used for recording informa-
tion extracted from patients’ cards. This form is developed
using the standardized ART entry and follow up form
employed by the ART clinic. The CD4 count laboratory
results recorded before starting ART were used as a base
line values. If there is no pre-treatment laboratory test,
however, results obtained within one month of ART initi-
ation were considered as baseline values. Four experienced
ART nurses who were trained on comprehensive HIV care
and involved in patient follow ups collected the data. Data
collection was supervised by the researchers. All com-
pleted data collection forms were examined for clarity and
consistency. The data were entered and cleaned by trained
data clerks and the investigators before analysis.Death was ascertained by reviewing cards and death
certificates. Patients who died from unrelated diseases or
accident were considered as censored, as well as those
alive at the end of the follow up period.
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Descriptive statistics such as median, mean, SDs and
tables were be used to investigate the characteristics of
the cohort. Person years of follow up were calculated by
assessing the date of enrollment for ART and death or
censoring. Survival analysis and the Kaplan-Meier test
were used to investigate factors that influence time to
death. Hazard ratios (HR), as well as 95% confidence
intervals were used as effect measures. A p-value of 0.05
was used. Descriptive statistics and Cox regression were
conducted using SPSSW version 16. Proportionality of
hazards test on Schoenfeld residuals and graph were
conducted using STATAW version 10.Ethical consideration
Ethical clearance was obtained from the Institutional Re-
search Ethics Review Committee (IRERC) of Haramaya
University. All information collected from patients cards
were kept strictly confidential and names were not
included in the abstracted data.Results
Characteristics of patients
A total of 1540 study participants were included in
the study. The sample comprised 963 (62.5%) females
and 574 (37.3%) males respectively. The median and
inter-quartile range (IQR) age was 32 and 28–40. The
majority of participants 1074 (69.9%) were Orthodox
Christians and 305 (19.8) were Muslim. Clinically, 890
(58.2%) and 348 (22.7%) patients were on the stage III
and II. The median (IQR) baseline CD4 count was
135 (76.0–198.3) per milliliter (Table 1).Figure 1 Survival functions stratified according to WHO clinical stagin
treatment in eastern Ethiopia (y-axis truncated to improve visibility).Follow up and survival patterns of the cohort
From the registered patients in this cohort analysis, the
outcome of patients as active, deceased, lost to follow up
and transfer out were 1005 (67.2%), 86 (5.9%), 210
(14.0%) and 192 (12.8%) respectively. There were 86
deaths in 4234.8 person years of retrospective follow up
Figure 1 displays the survival patterns of the cohort
based on WHO clinical stage categories. The overall
mortality rate provides an incidence density of 2.03
deaths per 100 person years (95% CI 1.64–2.50). Out of
a total of 86 deaths over 60 month period; 63 (73.3%)
died during the first 12 months, 10 (11.6%) during the
second year, and 10 (11.6%) in the third year of follow
up. When the follow-up period was divided into 1-year
time bands (from ART initiation through 1 year, from
1 year through 2 years, and from 2 years though 3 years),
the mortality rates per 100 person years at risk were
55.67 (95% CI 43.48–71.26), 4.03 (95% CI 2.17–7.51),
and 0.31 (95% CI 0.18–0.54) respectively.Predictors of mortality
In univarite analysis, factors associated with the pre-
dictor of mortality were previous weight loss of more
than 10%, bedridden functional status at baseline, less
than 200 CD4 cells/ml and WHO stage IV patients.
Those patients who reported to have lost a weight of
more than 10% at baseline were 5 times more likely to
die compared to those who did not (hazard ratio, HR
4.41; 95% CI 1.08–17.92). Those patients who were bed-
ridden or non-ambulatory at the initiation of treatment
were five times more likely to die compared with those
that were working (HR 5.33; 95% CI 3.05–9.30). Those
patients whose CD4 cell count lied between 201–300g in HIV infected patients in a cohort of patients on antiretroviral
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whose CD4 count was less than 200 cells per milliliter
(HR 0.42; 95% CI 0.19–0.92).
In the multivariate analysis, five baseline factors were
independent predictors of mortality. WHO stage IV
patients were 3 times more likely to die compared to
stage I and II patients (HR 3.19; 95% CI 1.51–6.76). Bed-
ridden patients were four times more likely to die com-
pared with those patients who are working (HR 4.09;
95% CI 2.12–7.90). Patients who reported to have lost
more than 10% of their weight at baseline were 5 times
more likely to die compared to those patients who did
not (HR 4.93; 95% CI 1.20–20.41). Patients whose CD4Table 2 Predictors of mortality among a sample of HIV infect






























Stage I and II 1.00
Stage III 1.35 (0.77–2.36)
Stage IV 3.35 (1.80–6.24)
¥Global test of proportionality of hazards derived from Schoenfeld residuals not signcell counts between 201–300 were 60% less likely to die
compared to those whose CD4 counts less than 200 (HR
0.40; 95% CI 0.17–0.93). Those patients with primary
education were almost 3 times more likely to die than
illiterate counterpart (HR 2.79; 95% CI 1.26–6.16)
(Table 2).
Discussions
The findings indicate that from the registered cohort,
there were 86 deaths in 4234.8 years of retrospective fol-
low up, providing an incidence density of 2.03 deaths per
100 person years (95% CI 1.64–2.51). About 210 (14.0%)
patients were lost to follow up. Factors that wereed cohorts on anti-retroviral treatment in eastern Ethiopia
P-value ¥Adjusted HR (95% CI) P-value
0.131 1.02 (0.99–1.05) 0.156
1.00
0.819 1.16 (0.68–2.00) 0.584
1.00
0.539 0.98 (0.55–1.75) 0.939
1.00
0.827 0.94 (0.58–1.52) 0.788
1.00
0.694 0.97 (0.60–1.56) 0.884
1.00
0.193 2.79 (1.26–6.16) 0.011
0.331 1.40 (0.61–3.22) 0.435
1.00
0.337 1.14 (0.64–2.04) 0.651
0.000 4.09 (2.12–7.90) 0.000
1.00
0.038 4.93 (1.20–20.41) 0.027
1.00
0.029 0.40 (0.17–0.93) 0.034
0.428 0.86 (0.30–2.41) 0.77
1.00
0.294 1.60 (0.85–3.04) 0.15
0.000 3.19 (1.51–6.76) 0.002
ificant (df = 13, ch2 = 13, p = 0.108).
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den functional status at baseline, ≤200 CD4 cells/ml and
advanced stage patients.
Long-term retention of patients in antiretroviral treat-
ment is a prerequisite for achieving any adherence at all.
Various studies have shown that mortality during the
first 6 months after initiating ART is much higher than
in developed countries and retention of patients in pro-
grams is poor [4,13]. However, most longitudinal studies
conducted in Africa have been either short-term or have
involved small numbers of participants.
In our study, the overall mortality rate of 2.03 deaths
per 100 person years is lower or comparable to that
reported elsewhere; however the mortality rate at the
first year (55.67; 95% CI 43.5–71.3; or 4.3%) is high. In
the ART-LINC Collaboration, which analyzed data from
18 cohorts across the developing world, mortality aver-
aged 4.2% across all 18 cohorts in the first year after ini-
tiation [11]. In Yaounde, Cameroon, from 312 patients,
the incidence rate of mortality rate was 21.2 per 100 per-
son years (95% CI 15–31) [14]. In southern Ethiopia, the
mortality rate was 15.4 per 100 person-years of observa-
tion [12]. The majority or 74.1% of the deaths occurred
in the first year after treatment. The study highlights the
high early mortality in ART cohorts in resource-limited
settings that has been observed by other groups in simi-
lar settings [4,15,16].
The primary causes of death in AIDS patients could be
the causes such immune reconstitution syndrome and
opportunistic infections as a result of very weak immun-
ity levels. In our study one of the factors associated with
early mortality is late presentation for ART. This may
also account for the high rate of death in the first year.
According to reports, patients that start ART at WHO
Stage III and IV are at an increased risk of dying [17,18].
Furthermore, early mortality risk is higher among those
with low CD4 cell count [4,19]. The CD4 count is a
proxy indicator of severity of disease which corresponds
to the functional status and reflects the immune state of
patients [20]. In our study, the functional status of
patients at the entry level had a positive correlation with
their disease stage and negative correlation with CD4
count. In a report from Hong Kong, there was a 79% re-
duction in mortality among ART taking patients with
CD4 counts of less than 200/ml [21]. The majority of
morbidity and mortality seen among individuals starting
ART with low baseline CD4 cell count occurs during the
first 3–6 months on treatment [2,3,15,16,22]. In one
study patients initiating ART with a base-line CD4 cell
count of less than 50 cells/mm3 had a 3.2-fold higher
mortality rate (p 0.004) compared with patients with a
CD4 cell count between 51 and 200 cells/mm3 at the
time of ART initiation [23]. Patients starting treatment
with CD4 cell count below 100 cells/mm3 were atsignificantly greater risk of death during the follow-up
period (OR 2.69; 95% CI 1.12–6.44) [12].
Nutritional and physical status can predict early mor-
tality. In our study, 10% weight loss determines mortality
during the course of treatment. In a district hospital in
Ethiopia, weight loss was seen in about a third of
patients who survived up to the fourth week, and it was
associated with increased death [18]. Higher body weight
at baseline was found to be associated with lower risk of
mortality with a HR of 0.58 for weight groups of 40–50
kilograms compared with the reference of less than 40
kilograms, and HR of 0.25 for groups ≥60 kilograms
compared with the reference groups (p< 0.013). The two
year patient survival was significantly related with co-tri-
moxazole initiation at or before treatment, clinical stage
IV disease, working functional status and weight greater
than 60 kilograms [24]. In another study, baseline body
mass index (BMI) of less than 18.5 was independently
associated with early mortality risk [19].
About 61% of patients in this study had education
below secondary school. According to reports, low edu-
cational level among patients is a contributing factor to
late presentation for ART [25]. This is understandable
since the more educated a patient is the better their
understanding of the disease state and comprehension of
instructions given on drug usage. These could enhance
treatment outcomes [26]. A report from British
Columbia reported a protective effect of educational
level on mortality from all causes among intravenous
drug users receiving anti-retroviral treatment [27,28].
Most reports suggest that low educational level has con-
sistently been associated with higher mortality, both
overall and cause-specific [29,30]. In our study lower
educational level was associated with a higher risk of
mortality. However, patients with primary education
seem to be at higher risk of death compared to those
with no education. This is an interesting finding for
which we could not find explanation due to the nature
of our data, however it needs further investigation in fu-
ture research.
This study has limitations. CD4 cell counts and HIV
RNA measurements were not available for all patients
because of cost issues. Diagnostic tests that would con-
firm the presence of certain opportunistic infections
were limited; as a result we were not able to include
these in our analysis. The retrospective cohort study de-
sign limited our ability to gather data about factors that
may influence the risk of mortality, for instance factors
such as lack of social supports networks, disclosure of
infection status and depression. Data was collected from
those who were attending ART centers mostly through
self-reporting and hence may have reporting and recall
bias. In ART programs of developing countries like Ethi-
opia, poor ascertainment of deaths and recording of
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estimation of mortality rates.
In conclusion, we detected a relatively lower level of
mortality among the cohort of patients on antiretroviral
treatment in eastern Ethiopia. Previous history of weight
loss, bedridden functional status at baseline, low CD4 cell
count and advanced WHO patients had a higher risk of
death among the retrospective cohort. So early initiation
of ART while CD4 counts are higher and opportunistic
infections limited, provision of nutritional support and
strengthening the food by prescription initiative, and
counseling of patients for early presentation during test-
ing for HIV is recommended.
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